Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

EarningsJoenjaPositive

AI Analysis

Summary

Pharming reported Q2 and H1 2026 financial results and revised year-end guidance, citing strong momentum for Joenja with near-term clinical readouts expected to support broader therapeutic use.

Financial Highlights

Guidance

revised year-end guidance

Importance:5/10

Sentiment:

0.60

earningsfinancial resultsguidance revisionJoenjaclinical readouts

Related Companies

$PHAR

Read the original article

Published by yahoo_finance on July 30, 2026 5:00 AM

Read Original